China-US Tensions Rise Sharply On Pelosi Visit, Will Biotech Get Burned?
Economic Countermeasures Already Taken
Where once there were promising prospects for cross-strait collaboration, biopharma firms in mainland China and Taiwan may now find themselves looking elsewhere for partners following a controversial visit to Taipei by US House Speaker Nancy Pelosi.
You may also be interested in...
Join our China-based content team for this latest Chinese-language podcast episode discussing selected hot topics impacting the biopharma industry in China, including a homegrown COVID-19 antiviral approval, ADC deals and cross-strait tensions and their impact on the biotech sector.
Amid simmering regional geopolitical tensions, speakers at a recent conference highlighted the multiple benefits of conducting clinical trials in Taiwan, while pointing to what more could be done to improve the local ecosystem.
A new commissioner has taken the reins at China's National Medical Products Administration, but the senior CCP official has so far given few clear indications about the changes he might bring.